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Studies in animal models show that the primary mechanism by which heme-oxygenases impart beneficial effects is
due to the gaseous molecule carbon monoxide (CO). Produced in humans mainly by the catabolism of heme by
heme-oxygenase, CO is a neurotransmitter important for multiple neurologic functions and affects several
intracellular pathways as a regulatory molecule. Exogenous administration of inhaled CO or carbon monoxide
releasing molecules (CORM’s) impart similar neurophysiological responses as the endogenous gas. Its’ involvement
in important neuronal functions suggests that regulation of CO synthesis and biochemical properties may be
clinically relevant to neuroprotection and the key may be a change in metabolic substrate from glucose to lactate.
Currently, the drug is under development as a therapeutic agent and safety studies in humans evaluating the safety
and tolerability of inhaled doses of CO show no clinically important abnormalities, effects, or changes over time in
laboratory safety variables. As an important therapeutic option, inhaled CO has entered clinical trials and its clinical
role as a neuroprotective and neurotherapeutic agent has been suggested. In this article, we review the
neuroprotective effects of endogenous CO and discuss exogenous CO as a neuroprotective and neurotherapeutic
agent.Introduction
CO is critical in the brain for a host of functions. Involve-
ment of carbon monoxide (CO) in several aspects suggests
that agents affecting the synthesis, transactions, and dispos-
ition of the gas have clinical relevance to neuroprotection
[1,2]. Endogenous production originates from heme
metabolism (at least 86%) and heme-independent sources
which include auto- and enzymatic oxidation of phenols,
photo-oxidation of organic compounds, iron-ascorbate
-catalyzed lipid peroxidation of microsomal lipids and
phospholipids, and reduction of cybochrome b5. Heme
oxygenase isozymes catalyze the first and rate-limiting step
in the degradation of heme to iron, biliverdin, and CO. The
cytoprotective effects of the heme oxygenases are attributed
to the production of CO. The majority of CO formed is
taken up in the cytosol before being released and combined
with hemoglobin and thus, correlation of carboxyhemoglo-
bin (COHb) levels with biological changes induced by CO
and remnant effects of CO after COHb elimination is poor.
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reproduction in any medium, provided the orproduction in humans described by Coburn and colleagues
allows calculation of the rate of heme catabolism with a
precision of ± 2 μmol/h and is applicable as a diagnostic
and therapeutic tool in neurophysiology, neurometabolism,
and neurologic pathologies [3].
Production and neuroprotective effects of
endogenous carbon monoxide
Endogenous formation of neuronal CO is dependent
on the expression of brain heme oxygenases. Heme
oxygenase-1 (HO-1) is primarily localized in endoplas-
mic reticulum, but has been isolated in cytoplasm,
nuclear matrix, mitochondria, and peroxisomes. Under
basal conditions, tissues not involved in red blood cell or
hemoglobin metabolism have low to undetectable
levels, but the enzyme is ubiquitously induced. Heme
oxygenase-2 (HO-2) proteins are primarily anchored to
the endoplasmic reticulum. These two isoforms have been
extensively investigated. Hayashi and colleagues studied the
structure of the third isoform (heme oxygenase-3) in the
rat with genomic PRC and found two HO-3-related genes
(HO-3a and HO-3b). The authors suggest that HO-3 is
nonfunctional and that the HO-3a and HO-3b genes are
processed pseudogenes derived from HO-2 transcripts [4].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RT-PCR are greatest for HO-2 seen throughout the brain
at much higher levels than HO-1 and HO-3. The highest
levels of expression are in the cerebellum and the
hippocampus. HO-1 and HO-2 are detectable in both cor-
tical neurons and type I astrocytes [5]. The isoform HO-1
is highly expressed in select neurons in the hilus of the
dentate gyrus, hypothalamus, cerebellum, and brainstem
whereas HO-2 is more widely expressed in mitral cells in
the olfactory bulb, pyramidal cells in the cortex and hippo-
campus, granule cells in the dentate gyrus, and many
neurons in the thalamus, hypothalamus, cerebellum and
caudal brainstem [6]. Under normal conditions, the HO-2
constitutive isoform accounts for nearly all of brain heme
oxygenase activity and therefore CO production.
Physiologic functions in the brain attributed to endogen-
ous CO to date include regulation of the hypothalamic-
pituitary-adrenal axis, circadian rhythm control, odor
response adaptation, nociception and chemoreception
regulation, hearing, long-term potentiation, neuroendocrine
regulation, behavior modification, memory, and vision
[7-10]. The function of HO-2 in the central nervous system
have been defined using HO-2 gene deletion and pharma-
cological inhibitors/activators of the enzyme in animal
models and cultured cells of neurons, astrocytes, and cere-
bral vascular endothelial cells [11-16]. Studies by Doré and
colleagues showed that HO-2 deletion results in increased
neurotoxicity in cultured brain cells and increased damage
following transient cerebral ischemia in mice [17]. Several
authors have shown that pharmacologic inhibition or gene
deletion of brain HO-2 exacerbates oxidative stress induced
by seizures, glutamate, and inflammatory cytokines, and
causes cerebral vascular injury [18-22]. Exposure of cortical
neurons to glutamate increases HO-2 activity and CO pro-
duction by calcium-calmodulin in a calcium-dependent
manner, a process that occurs in milliseconds [23]. Heme
oxygenase-2 is also activated during neuronal stimulation
by phosphorylation by CK2 and may be more long-term
[24]. Stimulation of metabotropic and ionotropic glutamate
receptors lead to increased CO production as well [25-27].
Brain homeostasis and neuronal survival during seizures,
hypoxia and hypotension correspond to upregulation of
HO-2 expression with CO production and resulting neuro-
protection [28].
The inducible isoform HO-1 has been targeted for
neuroprotection and neuroinflammation in several
diseases. Evidence suggests that the pathogenesis of sev-
eral neurodegenerative diseases including Parkinson’s
disease, Alzheimer’s disease, Friedreich’s ataxia, multiple
sclerosis, amyotrophic lateral sclerosis, and Huntington’s
disease may be due to formation of reactive oxygen spe-
cies and/or reactive nitrogen species with mitochondrial
dysfunction [29-31]. HO-1 induction with resultant for-
mation of CO is disrupted as is the protective systempotentially active against brain oxidative injury and has
been targeted for therapeutic interventions [32-36].
Exogenous carbon monoxide as a neuroprotector
The beneficial effects of HO-1 and HO-2 have been
attributed to CO. However neuroprotection using exogen-
ous CO as inhaled carbon monoxide (CO) or injectable car-
bon monoxide releasing molecules (CORM) is a novel and
underexplored strategy. Well known as a toxin at high
doses, exogenous CO also has critical physiologic and
cytoprotective properties at low concentrations and has
known anti-apoptotic, anti-inflammatory, antiproliferative,
and metabolic properties [37-41]. Studies by Vieira and
colleagues showed that the preconditioning of murine pri-
mary cerebellar granule cells with exogenous CO prevented
neuronal apoptosis induced by excitotoxicity and oxidative
stress [42]. Zeynalov and colleagues evaluated the role of
inhaled CO following 90-minutes of transient focal brain is-
chemia in a mouse model. Inhalation of 125 parts per mil-
lion (ppm) or 250 ppm CO begun immediately at the onset
of reperfusion resulted in reduction of hemispheric infarct
volume, improved neurological deficit scores, and limited
brain edema. Inhalation of 250 ppm CO begun 1 to 3 hours
after ischemia resulted in reduction of infarct volume and
improved neurological deficit scores [43]. Wang et al.
exposed male wild-type and Nrf2-knockout mice to 250
ppm CO or control air for 18 hours immediately after per-
manent middle cerebral artery occlusion. Nrf2 is the prin-
ciple transcription factor responsible for regulating HO-1
expression. CO neuroprotection was completely abolished
in Nrf2-knockout mice suggesting that the beneficial effect
of inhaled CO would at least partially be mediated through
the Nrf2 pathway and therefore likely HO-1 [44]. In our re-
cent report we found that piglets preconditioned with
inhaled CO had less apoptosis in the neocortex/striatum
and hippocampus after cardiopulmonary bypass (CPB) and
deep hypothermic circulatory arrest (DHCA). More-
over animals treated with CO demonstrated a change in
metabolic substrate utilization that correlated with neuro-
protection [45].
Exogenous carbon monoxide may change
neurometabolism and result in neuroprotection
Modulation of neurometabolic pathways and resultant
neuroprotection is likely dependent on the dose and timing
of exogenous CO administration, either pre, peri, or post
stressor. The challenge is to effect safe and effective CO
concentrations in neural tissues without producing deleteri-
ous effects and to define the neural cellular targets and
metabolic pathways. Recently, Queiroga and colleagues
concluded that CO controls mitochondrial functioning,
oxidative metabolism, and substrate utilization [46]. In the
intact brain, interactions between neurons and astrocytes
are requisite for brain energy metabolism, neuroprotection,
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tion and conduction, electrical energy being derived from
chemical processes through cerebral metabolism. Glucose
has been considered the obligatory substrate for brain
metabolism, but there has been continued debate as to the
primary energy substrate of brain cells during basal and
stressed conditions [47]. Distribution of energy substrates
from the systemic circulation into neurons is principally
determined by astrocytes and the dependence of cerebral
function on blood glucose as a fuel does not exclude lactate
or other substrates as an energy source. Lactate is used as a
metabolic substrate by the brain, but the blood–brain
transport of lactate is limited. Working brain tissue, how-
ever, releases large amounts of lactate. Uptake by carrier-
mediated facilitated diffusion is limited by dependence
on metabolism of accumulated lactate to maintain a
concentration gradient. At physiologically occurring lactate
concentrations, lactate uptake is at most 25% of the rate of
glucose oxidation. In the classical model of brain metabol-
ism, glucose can be utilized by both neurons and astrocytes
through oxidative metabolism. With normoxia, glucose
is readily consumed by both types of cells and lactate is
produced by both neurons and astrocytes. Lactate leaves
the astrocyte quickly, but little is transported out of the
neuron. ATP produced within the mitochondria are similar
between cells. However, ATP levels in the cytoplasm of
neurons can be much higher than what is present in the
cytoplasm of astrocytes. With hypoxia, glucose consump-
tion does not change significantly between cells, however,
lactate metabolism changes dramatically. Extracellular lac-
tate rises and mitochondria ATP production is slightly
reduced in both neurons and astrocytes. A second model of
brain energy metabolism, the astrocyte-neuron lactate shut-
tle hypothesis, allows that astrocytes consume glucose
through anaerobic glycolysis to pyruvate and then to lac-
tate. The lactate is secreted into the extracellular space and
can be taken up by neurons and used as a metabolic sub-
strate. Exogenous CO may result in a change in metabolic
substrate in the brain and may define the role of exogenous
CO in neurometabolism and, subsequent, neuroprotection.
This will be dependent as well on availability of specific
metabolic substrates.
In a rat hippocampal slice preparation, Schurr and
colleagues studied the combined effects of hypoxia and
lactic acidosis on neuronal function. There were no sig-
nificant decreases in recovery rate of synaptic function
between control slices and experimental slices that were
perfused with artifical cerebrospinal fluid containing
1.0, 2.0, 10.0, or 20.0 mM lactic acid 30 minutes before
and during hypoxic insult. The authors concluded that
neuronal tissue appears to be able to handle excess lac-
tic acid [48]. Several studies show that lactate may be
the preferred energy substrate of activated neurons and
is neuroprotective [49-54] and lactate may be a majorsubstrate for the mitochondrial tricarboxylic acid cycle.
Lactate preserves neuronal function in experimental
models of excitotoxicity, posthypoxic recovery, cerebral
ischemia, and energy deprivation and can sustain neur-
onal integrity as an alternative energy substrate. In
newborn piglets with intrauterine growth restriction
(IUGR), Moxon-Lester et al. showed that during hyp-
oxia brain lactate in some IUGR piglets were higher
than in other IUGR piglets and normal weight piglets
and that apoptosis in the frontal cortex and thalamus of
IUGR piglets with high brain lactate were lower than
IUGR piglets with low brain lactate. The authors concluded
that increased brain lactate during hypoxia may be
neuroprotective in IUGR piglets [55]. In a rat model of
acute/severe hypoglycemia, Won and colleagues concluded
that supplementation of glucose with lactate reduced neur-
onal death in the hippocampus and hypothesized that in-
creasing brain lactate in this model offsets the decrease in
NAD+ due to overactivation of PARP-1 by acting as an al-
ternative energy substrate that can effectively bypass gly-
colysis and be fed directly to the citric acid cycle to
maintain cellular ATP levels [56]. Our results in newborn
piglets preconditioned with inhaled CO before CPB/DHCA
are also consistent with a change to lactate as the metabolic
substrate and resulting neuroprotection [45].
Ca2+ signaling (which can be modulated by CO) may
control the switch between glucose and lactate utilization
during synaptic activity. (Figure 1) CO is able to regulate
several classes of ion channels including calcium activated
K(+), voltage-activaged K(+) and Ca(2+) channel families,
ligand-gated P2X receptors, tandem P domain K(+) and
channels and epithelial Na(+) channel. The calcium-
activated potassium channels (BK(Ca)) are distributed in
both excitable and non-excitable cells and are involved in
action potential repolarization, neuronal excitability, neuro-
transmitter release, hormone section, tuning of cochlear
hair cells, innate immunity, and modulation of smooth
muscle tone. These channels are highly sensitive to intra-
cellular calcium concentrations and voltage. Functionally,
they are able to decrease voltage-dependent Ca(2+) entry
through membrane hyperpolarization and serve as nega-
tive feedback regulators. The mechanisms by which CO
regulates the calcium channels are unclear, remain contro-
versial, and requires further study. However, Telezhkin and
colleagues found that cysteine residue 911 in the C-
terminal tail of human BK(Ca)α subunit is important for
activation by CO [57]. In cultured mouse glutamatergic
neurons, Bak et al. evaluated the effect of an ionomycin-
induced increase in intracellular Ca2+ on glucose and
lactate metabolism and concluded that glucose utilization is
positively correlated with intracellular Ca2+ but that lactate
utilization is not. The authors proposed a compart-
mentalized CiMASH (Ca2+-induced limitation of the












































Figure 1 Proposed mechanisms of effect of CO on presynaptic neurons and postsynaptic neurons on change to lactate as metabolic
substrate. Ca2+ signaling has been proposed as the primary determiner of change from glucose to lactate metabolism in the brain. CO could
block both NMDA R and VGCC allowing less Ca2+ to reach the cytoplasm. This would decrease the amount of glucose available for the
mitochondrial TCA cycle in both the presynaptic and postsynaptic neurons. Physiologic cystosol Ca2+ also binds to aralar which allows an
increase in malate transfer into the mitochondria and a change to the CiMASH pathway.
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plus lactate in which the latter displays a positive correl-
ation between oxidative metabolism of glucose and Ca2+
signaling [58].
Almeida and colleagues studied the effects of CO ex-
posure on primary cultures of astrocytes and showed
that CO prevented apoptosis, increased ATP, improved
oxidative metabolism, decreased lactate production,
reduced glucose use, increased cytochrome c oxidase en-
zymatic specific activity, stimulated mitochondrial bio-
genesis and enhanced Bcl-2 expression [59]. Vieira and
colleagues studied preconditioning of primary cultures of
mice cerebellar granule neurons with CO to prevent apop-
tosis induced by excitotoxicity (induced by glutamate) and
oxidative stress (induced by tert-butylhydroperoxide).
Pretreatment with CO protected neurons from apoptosis in
all ranges of glutamate concentrations tested and de-
creased neuronal apoptosis at 16 and 20 μM of the oxidant
agent after CO exposure. The authors evaluated the pre-
conditioning mechanism and propose that exogenous CO
induces intracellular ROS generation which activates nitric
oxide synthase (NOS) (increased NO production) that in
turn activates sGC leading to increased levels of cGMP and
the opening of ATP-dependent mitoKATP (important for
neuronal cell protection) [42]. In vivo studies have not been
done. Other proposed mechanisms for CO effects includemitochondrial biogenesis (more mitochondria are pro-
duced with the resulting increase in ATP production) and
improved oxidative phosphorylation. CO effects on mito-
chondria may be due to partial and/or reverse inhibition of
cytochrome c oxidase (complex IV) and/or accelerated
oxidative phosphorylation resulting in ROS as important
signalling molecules in the cell. CO inhibits loss of mito-
chondrial potential, and the opening of an 800 Da pore
through the inner membrane, resulting in swelling and
cytochrome c release.
Clinical application of inhaled carbon monoxide
for neuroprotection
Inhaled CO is an important therapeutic option and has
entered clinical trials (www.clinicaltrials.gov). Studies in
humans performed by INO Therapeutics LLC evaluated
the safety and tolerability of inhaled single doses of car-
bon monoxide when administered as an inhaled gas for
approximately 1 hour to healthy males (randomized, sin-
gle blind, placebo controlled in parallel groups). Doses of
0.2, 0.75, 2.0, and 2.3mg/kg/hr resulted in mean total max-
imum COHb levels of 2.0%, 3.4%, 7.7%, and 8.8%, re-
spectively. All doses were well tolerated. Analyses of
neurocognitive test data could not detect evidence of any
acute or delayed differences in response between exposure
to any of the carbon monoxide doses. The second study in
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domized, single-blind study conducted in four panels of
subjects. A total number of 12 healthy male volunteers
received carbon monoxide or placebo by inhalation (ten
subjects receiving CO and 2 subjects receiving placebo). In
Panel 1, 12 subjects were given repeated doses of 2.3mg
CO/kg or placebo during 1 hour for 10 consecutive days.
Panel 2 include 12 subjects receiving a single dose of 3.0
mg CO/kg or placebo. Panel 3 included 12 subjects given
repeated doses of 3.0mg CO/kg or placebo during 1 hour
for 10 consecutive days. Panel 4 was a crossover study that
included 12 subjects receiving a 3.0mg CO/kg single dose
sourced from a 5.97mg/L drug product and a 3.0mg CO/
kg single dose sourced from a 12mg/L drug product. The
highest level of COHb measured was 13.9% in the 3.0mg/
kg/hour dose. These studies indicate that inhaled CO is safe
and tolerable in humans. Clinical trials using inhaled CO
include Carbon Monoxide Therapy for Severe Pulmonary
Arterial Hypertension, Study of Inhaling Carbon Monoxide
to Treat Patients with Intestinal Paralysis after Colon
Surgery, Study of Inhaled Carbon Monoxide to Treat Idio-
pathic Pulmonary Fibrosis, Modification of Chronic Inflam-
mation by Inhaled Carbon Monoxide in Patients with
Stable Chronic Obstructive Pulmonary Disease (COPD),
and Carbon Monoxide to Prevent Lung Injury. Clinical
application in neurological disorders remains unexplored
however anecdotal data suggest that smokers have a very
low incidence of Alzheimers disease [60].
Preclinical studies of protective conditioning, a powerful
laboratory strategy used to evaluate metabolic pathways
and cell death, using many different stimuli show less
pathology in models of epilepsy, stroke, hypoxia-ischemia,
traumatic brain injury, and craniocerebral tumor resection
[61-71]. Clinical application of inhaled CO as a
neuroprotective agent (the agent does not have to be the
same as the potentially lethal insult) could be as a
preconditioning agent, postconditioning agent, and/or
periconditioning agent and may benefit patients undergo-
ing cardiopulmonary bypass for heart surgery, extracor-
poreal membrane oxygenation, resection of brain tumors/
abscesses or vascular malformations, deep hypothermic
circulatory arrest, radiation or chemotherapy for brain
tumors, traumatic brain injury, hypoxic injury of the new-
born, stroke, epilepsy, and neurodegenerative diseases.
Timing and dosing for maximum effect and safety needs
to be evaluated in clinical trials for these indications.
Conclusion
The role of CO in the brain and central nervous system
(CNS) has historically been negative, however recent data
as presented in this review suggests that this dogma needs
to be reevaluated. Endogenous CO is critical for normal
brain function. Clearly CO is produced in the brain as a
neurotransmitter and regulates memory and circadianrhythms. Therefore how can it also be so potently toxic.
The answer is, of course, the dose and duration of expos-
ure. The reports of the beneficial effects of CO in the brain
and CNS continue to emerge and serve as a call for this
simple gas to be reevaluated. Indeed, CO is currently being
tested in clinical trials after passing rigorous safety testing.
CO, like NO before it, may prove to be a therapeutic option
and a new and novel approach to various neuropathologies.
Clearly the time has come to reassess this simple gas as
one cannot ignore the remarkable data that continues to be
reported. The role for CO as a neurotherapeutic based on
compelling animal data necessitates further testing in
humans.
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